Personalis, Inc. to Provide Tumor Immunogenomic Profiling to the Parker Institute for Immunotherapy Biomarker Discovery in Clinical Trial Participants
MENLO PARK, Calif.--(BUSINESS WIRE)--May 22, 2019--
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the Parker Institute for Cancer Immunotherapy will utilize Personalis’ cancer immunogenomics platform, ImmunoID NeXT ™, for the investigation of biomarkers of response to immunotherapies in clinical trial participants. The trials include melanoma, pancreatic, and all-comer solid tumor patients treated with checkpoint inhibitors, either as monotherapy or in combination with other cancer therapeutics. This project builds on Personalis’ existing relationship with the Parker Institute as a contributing industry member of the TESLA Consortium, which focuses on improving neoantigen prediction algorithms.
Unlike traditional biomarker interrogation approaches that require several individual assays, which may be costly and time-consuming, and which may exhaust limited tumor tissue sample, ImmunoID NeXT™ consolidates multiple biomarker assays into one, meaning researchers no longer need to make the difficult choice regarding which biomarkers to analyze. The platform represents an end-to-end solution for immuno and precision oncology biomarker discovery applications, simultaneously enabling the analysis of: tumor mutations, neoantigens, immune repertoire clonality, tumor escape mechanisms (including HLA-related somatic mutations and genotyping), tumor mutational burden (TMB), microsatellite instability (MSI), oncoviruses, and more.
“Personalis’ platform could help us better understand which patients will respond or not respond to immunotherapy and why,” said Theresa LaVallee, PhD, VP Translational Medicine and Regulatory Affairs at the Parker Institute.
“We’re excited to work with the Parker Institute on this important new project,” said Dr. Richard Chen, MD, Personalis’ Chief Scientific Officer. “Both organizations are focused on improving outcomes for cancer patients, and we believe that ImmunoID NeXT™ is the catalyst that our partners and customers can leverage to discover more effective biomarkers of response to immunotherapies.”
About Personalis, Inc.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).
View source version on businesswire.com:https://www.businesswire.com/news/home/20190522005229/en/
CONTACT: Media Contact for Personalis:
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY PHARMACEUTICAL
SOURCE: Personalis, Inc.
Copyright Business Wire 2019.
PUB: 05/22/2019 08:05 AM/DISC: 05/22/2019 08:05 AM